New Ray Medicine International Holding Limited announced that based on a preliminary review and analysis of the latest available unaudited consolidated management accounts of the Company, it is expected that the Group will record a net loss of not more than HKD 3 million for the year ended 31 December 2021 ("FY 2021") as compared to the net loss of approximately HKD 69.7 million recorded by the Group for the year ended 31 December 2020 ("FY 2020").
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.051 HKD | -5.56% | +27.50% | +2.00% |
Mar. 25 | New Ray Medicine International Holding Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 18 | New Ray Medicine International Forecasts Decline in 2023 Loss | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+2.00% | 11.56M | |
-29.72% | 15.43B | |
-20.84% | 12.31B | |
-24.53% | 6.59B | |
+12.34% | 6.3B | |
-8.87% | 5.88B | |
-1.17% | 4.74B | |
+60.03% | 4.7B | |
-5.50% | 4.03B | |
-8.59% | 3.58B |
- Stock Market
- Equities
- 6108 Stock
- News New Ray Medicine International Holding Limited
- New Ray Medicine International Holding Limited Provides Unaudited Earnings Guidance for the Year Ended December 31, 2021